Your browser doesn't support javascript.
loading
Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design.
Riely, Gregory J; Ahn, Myung-Ju; Felip, Enriqueta; Ramalingam, Suresh S; Smit, Egbert F; Tsao, Anne S; Alcasid, Ann; Usari, Tiziana; Wissel, Paul S; Wilner, Keith D; Johnson, Bruce E.
Afiliación
  • Riely GJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Ahn MJ; Department of Hematology and Oncology, Samsung Medical Center, Seoul, 06351, Republic of Korea.
  • Felip E; Oncology Department, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, 08035, Spain.
  • Ramalingam SS; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, 1066, CX, The Netherlands.
  • Tsao AS; Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, TX 77030, Houston.
  • Alcasid A; Clinical Development and Operations, Pfizer Inc., Collegeville, PA 19426, USA.
  • Usari T; Biostatistics, Pfizer, Milan, 20152, Italy.
  • Wissel PS; Clinical Development and Operations, Pfizer Inc., Collegeville, PA 19426, USA.
  • Wilner KD; Clinical Development and Operations, Pfizer Inc., San Diego, CA 92121, USA.
  • Johnson BE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Future Oncol ; 18(7): 781-791, 2022 Mar.
Article en En | MEDLINE | ID: mdl-34918546
Plain language summary Some people with non-small-cell lung cancer (NSCLC) have changes in a gene called BRAF (known as 'gene mutations'). One common BRAF mutation is called 'V600'. Combinations of medicines that block proteins encoded by mutant BRAF and another gene called MEK can shrink tumors and slow their progression. We describe the design of PHAROS, a clinical trial investigating encorafenib (mutant BRAF inhibitor) combined with binimetinib (MEK inhibitor) in people with BRAFV600-mutant NSCLC that had spread to other parts of the body ('metastatic disease'). People are monitored for side effects and to see if their tumor shrunk. PHAROS includes people treated with encorafenib plus binimetinib as their first treatment for metastatic disease, and people whose cancer progressed after previous anticancer therapy. Clinical trial registration: Clinicaltrials.gov (NCT03915951) and EudraCT (2019-000417-37).
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Proteínas Proto-Oncogénicas B-raf / Neoplasias Pulmonares Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Future Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Proteínas Proto-Oncogénicas B-raf / Neoplasias Pulmonares Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Future Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido